FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

The FDA has just fired its lat­est sal­vo at the SGLT class of di­a­betes drugs, blow­ing up some com­mer­cial op­por­tu­ni­ty at As­traZeneca as part of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.